The αGC-treated WT group exhibited a substantial increase in systemic IFN-γ levels, hepatic enzymes (ALT and AST), and a significant reduction in the number of lung nodules in comparison to the non-treated group (Figures 4A–4D), reinforcing the notion that in addition to controlling tumor growth, αGC immunotherapy also results in liver injury. The gene discussed is IFNG; the disease is neoplasm.